Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29491152 | 1.00 | MAPT (0.44) | MAPTNR1H2ALDH1A1LMNAMEN1 | |
| SCHEMBL18291495 | 0.93 | NR1H2 (0.42) | MAPTNR1H2ALDH1A1LMNAMEN1 | |
| SCHEMBL20037632 | 0.89 | MAPT (0.43) | MAPTNR1H2ALDH1A1LMNAMEN1 | |
| SCHEMBL14845641 | 0.88 | MAPT (0.48) | MAPTNR1H2ALDH1A1LMNAMEN1 | |
| SCHEMBL22650785 | 0.87 | POLB (0.44) | MAPTNR1H2ALDH1A1LMNAMEN1 | |
| SCHEMBL29462384 | 0.87 | POLB (0.44) | MAPTNR1H2ALDH1A1LMNAMEN1 | |
| SCHEMBL1584044 | 0.86 | GPR119 (0.48) | MAPTNR1H2ALDH1A1LMNAMEN1 | |
| SCHEMBL255156 | 0.84 | MAPT (0.51) | MAPTNR1H2ALDH1A1LMNAMEN1 | |
| SCHEMBL29491170 | 0.84 | MAPT (0.51) | MAPTNR1H2ALDH1A1LMNAMEN1 | |
| SCHEMBL76458 | 0.84 | NR1H2 (0.54) | MAPTNR1H2ALDH1A1LMNAGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2026-05-28 | — | — | US | disclosed |
| WO-2025235363-A1 | CYCLIN-DEPENDENT KINASE 4 DEGRADERS | BLUEPRINT MEDICINES CORPORATION (US) | 2025-11-13 | — | — | WO | disclosed |
| CN-120040446-A | CDK inhibitors | 基因泰克公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20240043428-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LTD. (GB) | 2024-02-08 | — | — | US | disclosed |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20220296595-A1 | CDK INHIBITORS | GENENTECH, INC. | 2022-09-22 | — | — | US | disclosed |
| CN-110036012-B | Pyrido [3,4-d ] pyrimidine derivatives and pharmaceutically acceptable salts thereof | 帝人制药株式会社 | 2022-05-10 | — | — | CN | disclosed |
| CN-114364675-A | CDK inhibitors | 上海齐鲁锐格医药研发有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-11261182-B2 | Crystal of pyrido[3,4-d]pyrimidine derivative or solvate thereof | TEIJIN PHARMA LIMITED (JP) | 2022-03-01 | — | — | US | disclosed |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2011-06-23 | — | — | US | disclosed |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2011-06-23 | — | — | US | disclosed |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2011-06-23 | — | — | US | disclosed |
| EP-2331547-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | Novartis AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| WO-2010020675-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | NOVARTIS AG (CH) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010020675-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | NOVARTIS AG (CH) | 2010-02-25 | — | — | WO | disclosed |
| CN-1980923-A | Polycyclic pyridines as potassium ion channel modulators | ICAGEN INC (US) | 2007-06-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK9, CDK6, CDK7 | MAPT 3344/4885NR1H2 4468/4885ALDH1A1 3935/4885 |
| US-11261182-B2 | Crystal of pyrido[3,4-d]pyrimidine derivative or solvate thereof | CDK6, CDK4, CDKL4 | MAPT 2457/4885NR1H2 3474/4885ALDH1A1 2897/4885 |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | MAPT 2945/4885NR1H2 4214/4885ALDH1A1 3688/4885 |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | MAPT 3156/4885NR1H2 4055/4885ALDH1A1 2992/4885 |
| US-20240043428-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | MAPT 2945/4885NR1H2 4214/4885ALDH1A1 3688/4885 |
| US-20220296595-A1 | CDK INHIBITORS | CDKL1, CDK9, CDK6 | MAPT 2167/4885NR1H2 2826/4885ALDH1A1 2806/4885 |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | MAPT 2945/4885NR1H2 4214/4885ALDH1A1 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.